News
News
Digital/ News/ News/ News/ News/ Patients/ R&D
UK adds £175m funding to clinical research recovery drive
Phil Taylor
access, clinical research, clinical trials, digital, digital health, UK
0 Comment
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Phil Taylor
9 Meters Biopharma, gastrointestinal, Gattex, short bowel syndrome, Takeda, vurolenatide
0 Comment
Teva poaches Vertex exec as new head of R&D
Phil Taylor
R&D, senior management, Teva, Vertex Pharma
0 Comment
News/ News/ Sales and Marketing
Bayer grabs Chinese okay for CKD therapy Kerendia
Phil Taylor
Bayer, China, chronic kidney disease, Kerendia, regulatory approval
0 Comment
News/ News/ News/ Oncology/ R&D
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
Phil Taylor
BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab
0 Comment
News/ News/ News/ Oncology/ R&D
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Phil Taylor
AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo
0 Comment
News/ News/ News/ Oncology/ R&D
Blueprint cashes in on the past to build its future
Phil Taylor
Ayvakit, Blueprint Medicines, financing, Gavreto, royalty pharma, sixth street
0 Comment
Liver injuries prompt clinical hold on Sanofi BTK drug
Phil Taylor
Biogen, BTK inhibitor, Merck KGaA, multiple sclerosis, myasthenia gravis, Roche, safety, Sanofi
0 Comment